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Abstract
Objective: People with Parkinson disease (PD) frequently develop dementia,
which is associated with neocortical deposition of alpha-synuclein (a-syn) in
Lewy bodies and Lewy neurites. In addition, neuronal loss and deposition of
aggregated a-syn also occur in multiple subcortical nuclei that project to neo-
cortical, limbic, and basal ganglia regions. Therefore, we quantified regional
deficits in innervation from these PD-affected subcortical nuclei, by measuring
the neurotransmitters and neurotransmitter transporter proteins originating
from projections of dopaminergic neurons in substantia nigra pars compacta,
serotonergic neurons in dorsal raphe nuclei, noradrenergic neurons in locus
coeruleus, and cholinergic neurons in nucleus basalis of Meynert. Methods:
High-performance liquid chromatography and novel enzyme-linked
immunosorbent assays were performed to quantify dopaminergic, serotonergic,
noradrenergic, and cholinergic innervation in postmortem brain tissue. Eight
brain regions from 15 PD participants (with dementia and Braak stage 6 a-syn
deposition) and six age-matched controls were tested. Results: PD participants
compared to controls had widespread reductions of dopamine transporter in
caudate, amygdala, hippocampus, inferior parietal lobule (IPL), precuneus, and
visual association cortex (VAC) that exceeded loss of dopamine, which was only
significantly reduced in caudate and amygdala. In contrast, PD participants had
comparable deficits of both serotonin and serotonin transporter in caudate,
middle frontal gyrus, IPL, and VAC. PD participants also had significantly
reduced norepinephrine levels for all eight brain regions tested. Vesicular acetyl-
choline transporter levels were only quantifiable in caudate and hippocampus
and did not differ between PD and control groups. Interpretation: These
results demonstrate widespread deficits in dopaminergic, serotonergic, and
noradrenergic innervation of neocortical, limbic, and basal ganglia regions in
advanced PD with dementia.
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Introduction
The defining histopathologic feature of Parkinson disease
(PD) is the accumulation of misfolded alpha-synuclein
(a-syn) protein in Lewy bodies and Lewy neurites.1
Postmortem examinations of PD brains indicate stage-
dependent deposition of aggregated a-syn and topo-
graphical neuronal loss in multiple subcortical nuclei2
including substantia nigra, nucleus basalis of Meynert
(cholinergic),3 locus coeruleus (noradrenergic),4 and
dorsal raphe nuclei (serotonergic).5,6 Neocortical accu-
mulation of a-syn accompanies the development of
dementia that commonly occurs in PD and likely con-
tributes to impaired function of cortical neurons.7–9
However, the affected subcortical nuclei project rostrally
to striatal, limbic, and neocortical regions; and the loss
of innervation from these nuclei may also contribute to
impaired executive, visuospatial, attentional, and mem-
ory function in PD.
Cognitive and psychiatric changes in PD are linked in a
variety of ways to alterations in multiple neurotransmitter
systems.10–14 Previous studies have measured levels of
individual neurotransmitters or transporter proteins in a
limited number of regions such as caudate, putamen, and
neocortex.15–17 However, few studies have examined the
degree to which deficits in multiple neurotransmitter sys-
tems occur across neocortical and limbic regions.
The aim of the current study was to determine the
extent of regional deficits in dopaminergic, serotonergic,
noradrenergic, and cholinergic innervation in postmortem
tissue from those that had advanced PD and dementia and
neurologically normal controls. We combined measures of
neurotransmitters and corresponding transporter proteins
in basal ganglia, limbic, and neocortical regions. We used
high-performance liquid chromatography (HPLC) to mea-
sure neurotransmitter levels and developed novel sandwich
enzyme-linked immunosorbent assays (ELISAs) to mea-
sure relevant transporters. The results indicate widespread
loss of dopaminergic, serotonergic, and noradrenergic
innervation in advanced PD.
Materials and Methods
Standard protocol approvals and patient
consents
The Human Research Protection Office at Washing-
ton University in Saint Louis approved this study.
Written informed consent to perform a brain autopsy
was obtained from all participants. After death, the
immediate next-of-kin were contacted and confirmed
consent for brain removal and retention for research
purposes.
Study participants
The cohort included 15 PD participants with dementia and
six healthy age-matched neurologically normal control par-
ticipants. All PD participants and one control participant
were recruited through the Movement Disorders Center
(MDC), and five control participants were recruited
through the Knight Alzheimer Disease Research Center
(ADRC); both centers are located at Washington University
in Saint Louis. PD participants had a clear response to levo-
dopa (L-DOPA). Postmortem brain tissue was collected
between April 2008 and May 2013. Inclusion criteria for
the study were (1) PD participants who had a clinical diag-
nosis of idiopathic PD based on the United Kingdom
Parkinson Disease Society Brain Bank diagnostic criteria18
and either Clinical Dementia Rating (CDR global score) ≥1
or a clinical diagnosis of dementia; and (2) control partici-
pants with no family history of PD and no dementia
(CDR ≤ 0.5). Exclusion criteria for all participants were (1)
any neurological diagnosis other than PD; (2) psychiatric
disorders other than depression or anxiety; and (3) unwill-
ingness to consent to brain autopsy.
Motor assessments
MDC clinicians evaluated motor symptoms using the
Unified Parkinson Disease Rating Scale motor subscale III
(UPDRS-III). Evaluations were performed on anti-parkin-
sonian medications.
Dementia ratings
Dementia was rated using the CDR scale by experienced
raters. The CDR included assessment of whether cognitive
dysfunction was sufficiently severe to impair activities of
daily living. PD participants with CDR ≥ 1, in accordance
with criteria for dementia in PD,19 were included in the
study. PD participants were included in the study regard-
less of the time of onset of cognitive decline or dementia
(as elicited by history) relative to the onset of motor
symptoms.
Tissue dissection
The protocols to retrieve, dissect, preserve, perform
histology and immunohistochemistry, and diagnose with
established neuropathologic diagnostic criteria are rou-
tinely done in the Betty Martz Laboratory of the Knight
ADRC.20 The brain regions were dissected from frozen
1 cm coronal slices and included the body of the caudate
nucleus; gray matter from anterior cingulate gyrus
(ACG), middle frontal gyrus (MFG), inferior parietal lob-
ule (IPL), precuneus, and visual association cortex
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(VAC); hippocampus/entorhinal cortex; and amygdala.21
Detailed procedures of tissue handling and dissection are
described further in Data S1.
Extraction and analysis of
neurotransmitters by HPLC
Neurotransmitters dopamine (DA), serotonin (5HT), and
norepinephrine (NE) were extracted and analyzed by
HPLC with electrochemical detection using a method
modified from Xia et al.22 described in Data S1.
Extraction and analysis of neurotransmitter
transporter proteins by ELISA
The extraction method for transporter proteins was
adapted from previously published methods23 and is
described in Data S1. Capture and detection antibodies
used for dopamine transporter (DAT), serotonin trans-
porter (SERT), and vesicular acetyl choline transporter
(VAChT) sandwich ELISAs were screened from commer-
cially available antibodies (Table S1). DAT recombinant
protein from Novus Biologicals, LLC, Littleton, CO
(H00006531-P01) was used as a standard for DAT ELISA.
SERT and VAChT ELISAs used recombinant SERT and
VAChT that were expressed as his-tag proteins in
HEK293FT cells and purified by Nickel affinity chro-
matography based on previous methods,24 described in
more detail in Data S1. The sandwich ELISA protocols
were optimized for each neurotransmitter transporter
protein and also are described in detail in Data S1.
Statistical analysis
Data were analyzed using GraphPad Prism software, ver-
sion 4 (Graph Pad Software, Inc., La Jolla, CA) with
details described in Data S1. Due to unequal group sizes
and non-normal distribution of data points, nonparamet-
ric Mann–Whitney U tests were applied to compare
groups for HPLC and ELISA data. All tests were two-tailed
and corrected for multiple comparisons with the Holm–
Bonferroni method25 using a significance level of 0.05.
Results
Demographics and clinical information of
participants
Table 1 summarizes the demographics and clinical infor-
mation of the study participants. Age at death did not
significantly differ between control and PD participants
(Table 1). The male/female ratio was higher in PD
compared to controls (Table 1). Detailed clinical and
pathological information for each participant is included
in Table S2.
Assay performance characteristics for HPLC
and ELISA assays
The HPLC assay lower limits of quantification (LLOQs)
were 0.025 ng/mL for both DA and NE, and 0.10 ng/mL
for 5HT, corresponding to 0.125 ng/g wet wt for DA and
NE, and 0.5 ng/g wet wt for 5HT. The percent coeffi-
cients of variation (%CVs) for DA, 5HT, and NE assays
are reported in Table S3.
Specificity of the ELISA antibodies used for the quan-
tification of DAT, SERT, and VAChT were confirmed by
immunoprecipitation (IP) and western blotting (WB)
(Fig. S1). Representative standard curves for each ELISA
are shown in Fig. S2. The ELISA LLOQs for DAT, SERT,
and VAChT were 0.1, 0.016, and 0.3 ng/mL in the ELISA
well, respectively, which corresponded to 3.3, 0.5, and
9.9 ng/mL in the extracts, and 33, 5, and 99 ng/g wet wt
tissue. Since all group comparisons were performed for
an individual brain region within the same plate and no
comparisons were performed between plates, intraplate %
Table 1. Demographics and clinical information of the study
participants1.
Controls PD with dementia P
Demographics
Participants, N 6 15 NA
Age at death, y 84 (70–100) 79 (71–93) 0.512
Male/female, N 2/4 12/3 0.043
Clinical characteristics of PD participants with dementia
Age at PD diagnosis, y NA 63 (54–82) NA
Duration of motor
impairment, y
NA 14 (8–27) NA
UPDRS-III score
(OFF medications)
NA 44 (35–73.5) NA
LEDD, mg NA 800 (0–1350) NA










NA, not applicable; UPDRS, Unified Parkinson Disease Rating Scale;
LEDD, levodopa equivalent daily dose; SSRI, selective serotonin reup-
take inhibitors; AChE, acetylcholinesterase.




5Donepezil, rivastigmine, and galantamine.
6Quetiapine and clozapine.
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CVs were the most relevant measures of assay consistency,
which are included in Table S3.
Neurotransmitter and transporter measures
DA and DAT
PD participants had significantly lower DA levels com-
pared to control participants for caudate and amygdala
(Fig. 1, Table 2). DA levels for control and PD partici-
pants in MFG, ACG, hippocampus, IPL, precuneus, and
VAC did not significantly differ (Fig. 1). Table 2 lists
levels of DA in PD expressed as a percentage of controls
and their corresponding P values for all brain regions.
PD participants had widespread significant reductions in
DAT levels compared to control participants for caudate,
hippocampus, amygdala, IPL, precuneus, and VAC (Fig. 1,
Table 2). DAT levels in MFG and ACG did not significantly
differ between control and PD participants (Fig. 1, Table 2).
5HT and SERT
PD participants had significantly lower 5HT levels com-
pared to control participants for four of the eight brain
regions tested, which include caudate, MFG, IPL, and
VAC (Fig. 2, Table 2), whereas 5HT levels did not differ
between control and PD participants for ACG, hippocam-
pus, amygdala, and precuneus (Fig. 2, Table 2).
Similar to 5HT, PD participants also had significantly
lower SERT levels compared to control participants for
the same brain regions that include caudate, MFG, IPL,
and VAC (Fig. 2, Table 2), but not for ACG, hippocam-
pus, amygdala, and precuneus.
NE
PD participants had significantly lower NE levels com-
pared to control participants for all eight brain regions
tested, which include caudate, MFG, ACG, hippocampus,
amygdala, IPL, precuneus, and VAC (Fig. 3, Table 2).
VAChT
VAChT levels were below the LLOQ for samples from
MFG, ACG, amygdala, IPL, precuneus, and VAC. VAChT
levels were only quantifiable and did not significantly differ
between PD and control participants for caudate and
hippocampus (Fig. S3).
Neurotransmitter/transporter ratios
DA/DAT ratio was higher in caudate compared to other
brain regions in controls, whereas caudate DA/DAT was
dramatically lower in PD and similar to other regions in
PD (Table S4). 5HT/SERT ratios were similar across all
regions for controls and PD.
Relationship between neurochemical
measures, clinical and pathological features
We grouped PD participants (n = 15) according to differ-
ent pathological subtypes; a-syn only (n = 6); a-syn with
amyloid b (Ab) deposition (Braak amyloid stages B–C)
(n = 7); and a-syn with Ab plus at least moderate neocorti-
cal tau deposition (Braak tau stages 5–6) (n = 2).26 Since
the sample size for the a-syn with Ab plus tau group was
too low to allow statistical testing, we compared the a-syn
only and a-syn with Ab deposition groups and did not find
any significant group differences in any of the neurotrans-
mitter or transporter measures. Furthermore, we did not
find any significant correlations between neurochemical
measures and CDR, Mini Mental State Examination
(MMSE), or UPDRS-III scores within PD participants,
when corrected for multiple comparisons.
Discussion
Postmortem analysis of multiple brain regions in advanced
PD with dementia compared to age-matched neurologically
normal controls revealed widespread reductions in neuro-
transmitter levels of DA, 5HT, and NE, along with reduc-
tions in their corresponding transporter proteins, DAT and
SERT. PD participants had reduced dopaminergic innerva-
tion in six brain regions as reflected by significantly reduced
DAT levels in caudate, hippocampus, amygdala, IPL, pre-
cuneus, and VAC. Reduced DAT levels were accompanied
by reduced DA in only two regions (caudate and amyg-
dala), which likely reflects exogenous L-DOPA administra-
tion. PD participants had reduced serotonergic innervation
in four brain regions (caudate, MFG, IPL, and VAC). In
contrast to the dopaminergic system, regional reductions of
5HT matched that of SERT. Finally, PD participants had
marked reductions in noradrenergic innervation, reflected
by reduced NE levels in all brain regions tested including
caudate, MFG, ACG, hippocampus, amygdala, IPL, pre-
cuneus, and VAC. In contrast to the reductions in
dopaminergic, serotonergic, and noradrenergic systems, we
did not observe PD-related reductions in VAChT levels,
but we were only able to quantify VAChT in caudate and
hippocampus. The observed deficits in dopaminergic, sero-
tonergic, and noradrenergic innervation of multiple brain
regions provide insights into PD-related brain dysfunction,
particularly in the context of PD with dementia.
Measurements of DAT revealed more widespread
dopaminergic deficits compared to DA. Relative preserva-
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tion of DA levels in regions where DAT losses occur likely
reflects exogenous L-DOPA administration that increases
DA concentration in brain regions with residual DOPA
decarboxylase activity yet does not affect DAT on residual
dopaminergic presynaptic terminals. Similarly, exogenous
L-DOPA could lead to higher than normal levels of DA in
Figure 1. Comparison of DA and DAT levels between control and PD with dementia participants. DA and DAT levels in control and PD with
dementia for caudate (A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F),
precuneus (G), and visual association cortex (H). Statistically significant group differences (P < 0.05) are indicated by an asterisk. DA, dopamine;
DAT, dopamine transporter; PD, Parkinson disease.
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some cortical regions that could potentially relate to
drug-induced cognitive side effects.27 The differences in
DA/DAT ratios among different brain regions in controls
likely reflect regional differences in DOPA decarboxylase
and DA storage capacities for intact DAT-containing
presynaptic terminals. Alternatively, nonselective DA
uptake by SERT or NET also could influence DA/DAT
ratios.28 Higher levels of DA synthesis and storage com-
pared to DAT are likely to cause the significantly higher
DA/DAT ratio measured in caudate compared to cortical
regions in controls (caudate, 0.63; cortical regionsmedian,
0.02). The lower caudate DA/DAT ratio (0.08) in PD
patients indicates a relative loss in DA synthesis and stor-
age capacity for the remaining DAT-containing terminals.
In contrast, regional reductions of 5HT matched reduc-
tions of SERT in PD and the relative invariance of 5HT/
SERT ratios across regions in both controls and PD suggest
that exogenous drug administration does not influence
these ratios. PD-related degeneration of 5HT neurons
equally affects local 5HT concentration and presynaptic
terminal membranous SERT, a major difference between
the 5HT/SERT system and the DA/DAT system in PD.
Dramatic reductions of NE levels in all brain regions
reflects extensive loss of innervation from locus coeruleus
neurons, which may further contribute to cortical neuron
dysfunction related to local synucleinopathy in advanced
PD. The loss of NE secondary to locus coeruleus lesions
in animal models alters cerebral oxidative metabolism
and blood flow,29 which fits with the observed excessive
oxidative metabolism in mildly affected, never-medicated
PD patients and could indicate uncoupling of oxidative
phosphorylation.30 Altered oxidative metabolism as well
as other consequences of noradrenergic deficits, including
altered neuroinflammatory pathways,31–33 may contribute
to attention, cognitive, or mood dysfunction in PD.
Our observed neurotransmitter and transporter deficits
in caudate agree with a number of previous studies. The
reduced caudate levels of DAT for PD participants in our
study agree with previously reported reductions in striatal
DAT by autoradiography,34 immunohistochemistry and
WB,35 positron emission tomography (PET),15 and single
photon-emission computed tomography (SPECT) imag-
ing.36 The magnitude of DA and DAT reductions in cau-
date (2.5% and 17.5% of controls, respectively) is greater
in our study compared to two other studies, which
observed reductions in DA and DAT markers in caudate
ranging from 9% to 30% of controls, and more pro-
nounced reductions (2–3% of controls) in putamen.16,37
The reduced caudate SERT levels in our study agree with
previous measurements of caudate 5HT,38 and with previ-
ous measurements of caudate SERT levels by WB analy-
sis,16 PET,39 and SPECT imaging.40 Reduced caudate NE
was observed in one prior study,41 while another study
did not detect changes in caudate NE.37 Our VAChT
measurements are consistent with findings of in vivo PET
imaging in neurologically normal individuals, where the
density of VAChT is higher in the striatum and hip-
pocampus compared to neocortical regions.42,43
A few previous studies reported neurotransmitter
changes in cortical regions although they examined a
smaller number of regions compared to our study. Our
findings confirm the absence of significant DA loss in
frontal and cingulate cortex for PD participants on L-
DOPA despite reductions of DA in caudate.38 Similar
changes in the levels of 5HT were observed in frontal
cortex, but unlike our study, significant reductions of
5HT were observed in cingulate cortex.38 Interestingly,
the same group also observed widespread deficits in NE
levels in frontal, cingulate, hippocampus, and entorhinal
cortex, although the relative differences between control
and PD was less pronounced than in our study. The sig-
nificant reductions in NE in frontal cortex observed by
Goldstein et al.41 also agree with our study. Modest dis-
crepancies in findings between our study and these other
Table 2. Levels of neurotransmitters and transporters in PD with dementia as a percentage of controls in all brain regions.
DA DAT 5HT SERT NE
%C P %C P %C P %C P %C P
Caudate 2.5 0.001 17 0.003 31.6 0.003 38.5 0.007 7.3 0.001
MFG 158 0.79 97.3 0.5 19.7 0.001 19 0.005 9.65 0.001
ACG 120 0.9 115.4 0.8 52.5 0.011 68.3 0.17 3.9 0.002
Hippocampus 106 0.46 37.5 0.002 67.4 0.2 102.8 0.97 27.3 0.007
Amygdala 27.8 0.001 18.1 0.001 60.5 0.06 74.6 0.11 10.92 0.002
IPL 140.3 0.84 35 0.001 16.8 0.001 32.13 0.001 4.2 0.001
Precuneus 198.3 0.41 36.5 0.001 68.6 0.63 66.4 0.213 17.6 0.001
VAC 176 0.67 41.8 0.003 11.8 0.003 9.9 0.001 15.8 0.001
Shaded boxes represent measures that were significantly different between control and PD with dementia at P < 0.05, adjusted for multiple
comparisons performed for each measure. DA, dopamine; DAT, dopamine transporter; 5HT, serotonin; SERT, serotonin transporter; NE,
norepinephrine; C, control; MFG, middle frontal gyrus; ACG, anterior cingulate gyrus; IPL, inferior parietal lobule; VAC, visual association cortex.
954 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Neurotransmitter Deficits in PD with Dementia C. Buddhala et al.
studies may be related to differences in disease duration,
severity of disease, cognitive status, drug exposure, or
analysis methods.
Novel aspects of our study include the analysis of a large
number of brain regions, and the simultaneous
measurement of multiple neurotransmitters with their
Figure 2. Comparison of 5HT and SERT levels between control and PD with dementia participants. 5HT and SERT levels in control and PD with
dementia for caudate (A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F),
precuneus (G), and visual association cortex (H). Statistically significant group differences (P < 0.05) are indicated by an asterisk. 5HT, serotonin;
SERT, serotonin transporter; PD, Parkinson disease.
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corresponding transporters in a homogenous population of
end-stage PD. Such concurrent measurements have not
been reported previously, with the exception of two studies
that measured only striatal neurotransmitters and trans-
porters for just dopaminergic and serotonergic systems.16,37
Unlike PET44 or SPECT45 imaging radioligands that bind
to multiple members of the neurotransmitter transporter
family, the DAT, SERT, and VAChT ELISAs developed in
this study are highly specific based on the epitopes recog-
nized by the capture and detection antibodies. These mea-
sures were further validated using IP and WB. The results
from the novel ELISAs agree with previous findings of
transporter reductions, suggesting consistency and reliabil-
ity of the developed assays. Moreover, ELISAs offer an
advantage in sensitivity and throughput compared to
immunohistochemical or WB methods.16,35,46,47 Further-
more, the higher sensitivity of the ELISAs enabled quantifi-
cation of DAT and SERT in multiple cortical regions where
levels are significantly lower than caudate.
This study has several limitations. The modest sample
size and homogeneously severe cognitive impairment pre-
cluded analysis of whether the neurotransmitter or trans-
porter differences relate to specific cognitive phenotypes
associated with PD. The number of males and females was
not equal, particularly in the PD group. The higher per-
centage of males within the PD group reflects to some
extent the higher prevalence of PD in males,48,49 and also
may be explained by sex differences in participation in the
study or in the death rates among the PD participants. The
widespread and dramatic differences between PD and con-
trol participants are unlikely to be explained by differences
in sex ratios between the two groups, but the possibility
exists that sex may have small influences on baseline levels
which only can be excluded with further studies of larger
sample sizes. The small sample sizes (n = 2–3) obtained
when groups were subdivided based on sex prevented
within group or between group comparisons to investigate
this further using nonparametric statistics. Some measure-
ments demonstrate significant dispersion not only in PD
participants, where variability in disease manifestation may
contribute, but also in control participants. In addition to
biologic variability, additional contributing factors specific
to the nature of this study include variability related to
postmortem intervals, dissection of postmortem tissue, and
drug exposure. The lack of an ELISA for quantification of
NET limited our ability to further assess and confirm the
loss of noradrenergic innervation throughout the brain
regions examined. VAChT ELISA was not sufficiently sensi-
tive to measure VAChT levels in cortical regions, and thus
we were not able to determine whether degeneration of
nucleus basalis cholinergic neurons results in altered
cholinergic innervation of these brain regions.
Our results demonstrate widespread deficits in
dopaminergic, serotonergic, and noradrenergic innerva-
tion of neocortical, limbic, and basal ganglia regions in
advanced PD with dementia. Our data do not prove
Figure 3. Comparison of NE levels between control and PD with dementia participants. NE levels in control and PD with dementia for caudate
(A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F), precuneus (G), and visual
association cortex (H). Group differences were statistically significant for all of the brain regions tested (P < 0.05), as indicated by an asterisk. NE,
norepinephrine; PD, Parkinson disease.
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whether these findings reflect the presence or absence of
dementia. Future enrollment of additional PD partici-
pants with mild and no cognitive impairment will enable
further characterization of the range of neurotransmitter
and transporter deficits in PD, and determine whether
levels are correlated with specific cognitive phenotypes.
The novel DAT and SERT ELISAs could be further
extended to other disorders, such as schizophrenia, Tour-
ette’s syndrome, attention deficit hyperactivity disorder,
or depression, where dysregulation of DAT or SERT are
implicated.50–53 Furthermore, combining postmortem
measurements of neurotransmitters and their correspond-
ing transporters with in vivo PET imaging would be help-
ful to further define specific brain regions and
neurotransmitter systems affected in PD.
Acknowledgments
Support for this work was provided by a grant from the
Michael J. Fox Foundation, National Institutes of Health
grants NS075321, NS41509, NS058714, and NS48924 from
the National Institute of Neurological Disorders and Stroke;
P50AG005681 and P01AG003991 from the National Insti-
tute on Aging; UL1 TR000448 from the National Institutes
of Health National Center for Advancing Translational
Sciences; the American Parkinson Disease Association
(APDA) Advanced Research Center for Parkinson Disease
at Washington University in St. Louis; the Greater St. Louis
Chapter of the APDA; and the Barnes Jewish Hospital
Foundation (Elliot Stein Family Fund and Parkinson
Disease Research Fund). We are grateful for the technical
support of the Betty Martz Laboratory for Neurodegenera-
tive Research at Washington University in Saint Louis.
Author Contributions
Study concept and organization: Drs. Kotzbauer, Perlmut-
ter, Campbell, and Cairns; execution: Drs. Cairns,
Buddhala, Loftin, and Kuley; acquisition of data: Drs.
Campbell, Buddhala, Loftin, and Kuley; analysis and inter-
pretation of data: all authors; drafting of the manuscript:
Drs. Buddhala and Kotzbauer; critical revision of the
manuscript for important intellectual content: all authors;
statistical analysis: Drs. Campbell, Kotzbauer, and Bud-
dhala; obtained funding: Drs. Kotzbauer and Perlmutter.
Drs. Kotzbauer and Campbell had full access to all of the
data in the study and take responsibility for the integrity
of the data and the accuracy of the data analysis.
Conflict of Interest
The sponsors had no role in the design and conduct of
the study; collection, management, analysis, and interpre-
tation of the data; preparation, review, or approval of the
manuscript; and decision to submit the manuscript for
publication.
References
1. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-
synuclein in filamentous inclusions of Lewy bodies from
Parkinson’s disease and dementia with Lewy bodies. Proc
Natl Acad Sci USA 1998;95:6469–6473.
2. Braak H, Ghebremedhin E, Rub U, et al. Stages in the
development of Parkinson’s disease-related pathology. Cell
Tissue Res 2004;318:121–134.
3. Bohnen NI, Albin RL. The cholinergic system and
Parkinson disease. Behav Brain Res 2011;221:564–573.
4. Gesi M, Soldani P, Giorgi FS, et al. The role of the locus
coeruleus in the development of Parkinson’s disease.
Neurosci Biobehav Rev 2000;24:655–668.
5. Guttman M, Boileau I, Warsh J, et al. Brain serotonin
transporter binding in non-depressed patients with
Parkinson’s disease. Eur J Neurol 2007;14:523–528.
6. Bosboom JL, Stoffers D, Wolters E. Cognitive dysfunction
and dementia in Parkinson’s disease. J Neural Transm
2004;111:1303–1315.
7. Compta Y, Parkkinen L, O’Sullivan SS, et al. Lewy- and
Alzheimer-type pathologies in Parkinson’s disease
dementia: which is more important? Brain 2011;134(Pt
5):1493–1505.
8. Hely MA, Reid WG, Adena MA, et al. The Sydney
multicenter study of Parkinson’s disease: the
inevitability of dementia at 20 years. Mov Disord
2008;23:837–844.
9. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein
cortical Lewy bodies correlate with dementia in Parkinson’s
disease. Neurology 2000;54:1916–1921.
10. Bosboom JL, Stoffers D, Wolters E. The role of acetylcholine
and dopamine in dementia and psychosis in Parkinson’s
disease. J Neural Transm Suppl 2003;65:185–195.
11. Halliday GM, Leverenz JB, Schneider JS, Adler CH. The
neurobiological basis of cognitive impairment in
Parkinson’s disease. Mov Disord 2014;29:634–650.
12. Huot P, Fox SH. The serotonergic system in motor and
non-motor manifestations of Parkinson’s disease. Exp
Brain Res 2013;230:463–476.
13. Riekkinen M, Kejonen K, Jakala P, et al. Reduction of
noradrenaline impairs attention and dopamine depletion
slows responses in Parkinson’s disease. Eur J Neurosci
1998;10:1429–1435.
14. Sawamoto N, Piccini P, Hotton G, et al. Cognitive deficits
and striato-frontal dopamine release in Parkinson’s
disease. Brain 2008;131(Pt 5):1294–1302.
15. Kazumata K, Dhawan V, Chaly T, et al. Dopamine
transporter imaging with fluorine-18-FPCIT and PET.
J Nucl Med 1998;39:1521–1530.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 957
C. Buddhala et al. Neurotransmitter Deficits in PD with Dementia
16. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of
serotonin markers in caudate versus putamen in
Parkinson’s disease. Brain 2008;131(Pt 1):120–131.
17. Shannak K, Rajput A, Rozdilsky B, et al.
Noradrenaline, dopamine and serotonin levels and
metabolism in the human hypothalamus: observations in
Parkinson’s disease and normal subjects. Brain Res
1994;639:33–41.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of
clinical diagnosis of idiopathic Parkinson’s disease: a
clinico-pathological study of 100 cases. J Neurol
Neurosurg Psychiatry 1992;55:181–184.
19. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic
criteria for dementia associated with Parkinson’s disease.
Mov Disord 2007;22:1689–1707; quiz 837.
20. Cairns NJ, Taylor-Reinwald L, Morris JC; Alzheimer’s
Disease Neuroimaging I. Autopsy consent, brain
collection, and standardized neuropathologic assessment
of ADNI participants: the essential role of the
neuropathology core. Alzheimers Dement
2010;6:274–279.
21. Nieuwenhuys R, Voogd J, Huijzen CV. The human central
nervous system: a synopsis and atlas. 3rd rev. ed. Berlin,
New York: Springer, 1988.
22. Xia Y, Cheng S, He J, et al. Effects of subchronic exposure
to benzo[a]pyrene (B[a]P) on learning and memory, and
neurotransmitters in male Sprague–Dawley rat.
Neurotoxicology 2011;32:188–198.
23. Worsley JN, Moszczynska A, Falardeau P, et al. Dopamine
D1 receptor protein is elevated in nucleus accumbens of
human, chronic methamphetamine users. Mol Psychiatry
2000;5:664–672.
24. Engel LA, Jing Z, O’Brien DE, et al. Catalytic function of
PLA2G6 is impaired by mutations associated with infantile
neuroaxonal dystrophy but not dystonia-parkinsonism.
PLoS One 2010;5:e12897.
25. Holm S. A simple sequentially rejective multiple test
procedure. Scand J Stat 1979;6:65–70.
26. Kotzbauer PT, Cairns NJ, Campbell MC, et al. Pathologic
accumulation of alpha-synuclein and Abeta in Parkinson
disease patients with dementia. Arch Neurol
2012;69:1326–1331.
27. Cools R, Stefanova E, Barker RA, et al. Dopaminergic
modulation of high-level cognition in Parkinson’s disease:
the role of the prefrontal cortex revealed by PET. Brain
2002;125(Pt 3):584–594.
28. Daws LC. Unfaithful neurotransmitter transporters: focus
on serotonin uptake and implications for antidepressant
efficacy. Pharmacol Ther 2009;121:89–99.
29. Harik SI, LaManna JC, Light AI, Rosenthal M. Cerebral
norepinephrine: influence on cortical oxidative metabolism
in situ. Science 1979;206:69–71.
30. Powers WJ, Videen TO, Markham J, et al.
Cerebral mitochondrial metabolism in early
Parkinson’s disease. J Cereb Blood Flow Metab
2008;28:1754–1760.
31. Heneka MT, Galea E, Gavriluyk V, et al. Noradrenergic
depletion potentiates beta -amyloid-induced cortical
inflammation: implications for Alzheimer’s disease.
J Neurosci 2002;22:2434–2442.
32. Marien MR, Colpaert FC, Rosenquist AC. Noradrenergic
mechanisms in neurodegenerative diseases: a theory. Brain
Res Brain Res Rev 2004;45:38–78.
33. O’Donnell J, Zeppenfeld D, McConnell E, et al.
Norepinephrine: a neuromodulator that boosts the
function of multiple cell types to optimize CNS
performance. Neurochem Res 2012;37:2496–2512.
34. Mizukawa K, McGeer EG, McGeer PL. Autoradiographic
study on dopamine uptake sites and their correlation with
dopamine levels and their striata from patients with
Parkinson disease, Alzheimer disease, and neurologically
normal controls. Mol Chem Neuropathol 1993;18:133–144.
35. Miller GW, Staley JK, Heilman CJ, et al. Immunochemical
analysis of dopamine transporter protein in Parkinson’s
disease. Ann Neurol 1997;41:530–539.
36. Booij J, Tissingh G, Boer GJ, et al. [123I]FP-CIT SPECT
shows a pronounced decline of striatal dopamine
transporter labelling in early and advanced Parkinson’s
disease. J Neurol Neurosurg Psychiatry 1997;62:133–140.
37. Wilson JM, Levey AI, Rajput A, et al. Differential changes
in neurochemical markers of striatal dopamine nerve
terminals in idiopathic Parkinson’s disease. Neurology
1996;47:718–726.
38. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of
cortical dopamine, noradrenaline, serotonin and their
metabolites in Parkinson’s disease. Brain Res
1983;275:321–328.
39. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron
emission tomography of striatal serotonin transporters in
Parkinson disease. Arch Neurol 2003;60:1223–1229.
40. Haapaniemi TH, Ahonen A, Torniainen P, et al.
[123I]beta-CIT SPECT demonstrates decreased brain
dopamine and serotonin transporter levels in untreated
parkinsonian patients. Mov Disord 2001;16:124–130.
41. Goldstein DS, Sullivan P, Holmes C, et al. Catechols in
post-mortem brain of patients with Parkinson disease. Eur
J Neurol 2011;18:703–710.
42. Kuhl DE, Minoshima S, Fessler JA, et al. In vivo mapping
of cholinergic terminals in normal aging, Alzheimer’s
disease, and Parkinson’s disease. Ann Neurol
1996;40:399–410.
43. Petrou M, Frey KA, Kilbourn MR, et al. In vivo imaging
of human cholinergic nerve terminals with (-)-5-(18)
F-fluoroethoxybenzovesamicol: biodistribution,
dosimetry, and tracer kinetic analyses. J Nucl Med
2014;55:396–404.
44. Remy P, Doder M, Lees A, et al. Depression in
Parkinson’s disease: loss of dopamine and noradrenaline
958 ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Neurotransmitter Deficits in PD with Dementia C. Buddhala et al.
innervation in the limbic system. Brain 2005;128(Pt
6):1314–1322.
45. Berding G, Brucke T, Odin P, et al. [[123I]beta-CIT
SPECT imaging of dopamine and serotonin transporters in
Parkinson’s disease and multiple system atrophy.
Nuklearmedizin 2003;42:31–38.
46. Gaspar P, Gray F. Dementia in idiopathic Parkinson’s
disease. A neuropathological study of 32 cases. Acta
Neuropathol 1984;64:43–52.
47. Siegal D, Erickson J, Varoqui H, et al. Brain vesicular
acetylcholine transporter in human users of drugs of
abuse. Synapse 2004;52:223–232.
48. Lubomski M, Louise Rushworth R, Lee W, et al. Sex
differences in Parkinson’s disease. J Clin Neurosci
2014;21:1503–1506.
49. Smith KM, Dahodwala N. Sex differences in Parkinson’s
disease and other movement disorders. Exp Neurol
2014;259:44–56.
50. Huang Y, Zheng MQ, Gerdes JM. Development of
effective PET and SPECT imaging agents for the serotonin
transporter: has a twenty-year journey reached its
destination? Curr Top Med Chem 2010;10:1499–1526.
51. Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic
dysbalance in distinct basal ganglia neurocircuits:
implications for the pathophysiology of Parkinson’s
disease, schizophrenia and attention deficit hyperactivity
disorder. Neurotox Res 2006;10:167–179.
52. Owens MJ, Nemeroff CB. Role of serotonin in the
pathophysiology of depression: focus on the serotonin
transporter. Clin Chem 1994;40:288–295.
53. Runyon SP, Carroll FI. Dopamine transporter ligands:
recent developments and therapeutic potential. Curr Top
Med Chem 2006;6:1825–1843.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Materials and methods.
Figure S1. Assessment of ELISA antibody specificity.
Figure S2. Representative standard curves for the trans-
porter ELISA assays.
Figure S3. Comparison of VAChT levels between control
and PD with dementia participants.
Table S1. Capture and detection antibodies used in the
ELISA assays.
Table S2. Clinical and pathological information of study
participants.
Table S3. Assay performance characteristics of HPLC and
ELISA assays.
Table S4. Ratios of neurotransmitters to transporters
between control and PD with dementia.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 959
C. Buddhala et al. Neurotransmitter Deficits in PD with Dementia
